Bioconversion of the anthracycline analogue desacetyladriamycin by recombinant DoxA, a P450-monooxygenase from Streptomyces sp. strain C5

Robbie J. Walczak, Jennifer V. Hines, William R. Strohl, Nigel D. Priestley

Research output: Contribution to journalArticlepeer-review

Abstract

(matrix presented) A recombinant P450-monooxygenase, DoxA, obtained from Streptomyces sp. strain C5, the producer of the anticancer compound daunorubicin, was expressed in S. lividans TK24 and therein used to catalyze the conversion of the anthracycline analogue desacetyladriamycin into the new anthracycline, 10-hydroxydesacetyladriamycin. This work establishes a new function for DoxA and demonstrates the use of a recombinant enzyme to prepare a new anthracycline analogue.

Original languageEnglish
Pages (from-to)2277-2279
Number of pages3
JournalOrganic Letters
Volume3
Issue number15
DOIs
StatePublished - Jul 26 2001

Fingerprint

Dive into the research topics of 'Bioconversion of the anthracycline analogue desacetyladriamycin by recombinant DoxA, a P450-monooxygenase from Streptomyces sp. strain C5'. Together they form a unique fingerprint.

Cite this